Author(s): Achiron A, Chapman J, Magalashvili D, Dolev M, Lavie M, et al.
Background/aims:Large-scale population studies measuring rates and dynamics of cognitive decline in multiple sclerosis (MS) are lacking. In the current cross-sectional study we evaluated the patterns of cognitive impairment in MS patients with disease duration of up to 30 years.
Methods:1,500 patients with MS were assessed by a computerized cognitive battery measuring verbal and non-verbal memory, executive function, visual spatial perception, verbal function, attention, information processing speed and motor skills. Cognitive impairment was defined as below one standard deviation (SD) and severe cognitive impairment as below 2SD for age and education matched healthy population norms.
Results:Cognitive performance in our cohort was poorer than healthy population norms. The most frequently impaired domains were information processing speed and executive function. MS patients with secondary-progressive disease course performed poorly compared with clinically isolated syndrome, relapsing-remitting and primary progressive MS patients. By the fifth year from disease onset, 20.9% of patients performed below the 1SD cutoff for impairment, p=0.005, and 6.0% performed below the 2SD cutoff for severe cognitive impairment, p=0.002. By 10 years from onset 29.3% and 9.0% of patients performed below the 1SD and 2SD cutoffs, respectively, p=0.0001. Regression modeling suggested that cognitive impairment may precede MS onset by 1.2 years.
Conclusions:The rates of cognitive impairment in this large sample of MS patients were lower than previously reported and severe cognitive impairment was evident only in a relatively small group of patients. Cognitive impairment differed significantly from expected normal distribution only at five years from onset, suggesting the existence of a therapeutic window during which patients may benefit from interventions to maintain cognitive health.
Referred From: https://pubmed.ncbi.nlm.nih.gov/23936485/
Author(s): Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL
Author(s): Beard S, Hunn A, Wight J
Author(s): Shakespeare DT, Boggild M, Young C
Author(s): Russo EB
Author(s): Schoedel KA, Chen N, Hilliard A, White L, Stott C, et al.
Author(s): Wade DT, Makela P, Robson P, House H, Bateman C
Author(s): Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group
Author(s): Novotna A, Mares J, Ratcliffe S, Novakova I, Zapletalova O, et al
Author(s): Wade DT, Collin C, Stott C, Duncombe P
Author(s): Serpell MG, Notcutt W, Collin C
Author(s): Mechoulam R, Parker LA
Author(s): Bovasso GB
Author(s): Degenhardt L, Hall W, Lynskey M
Author(s): Lynskey MT, Glowinski AL, Todorov AA, Bucholz KK, Madden PA, et al.
Author(s): Dougherty DM, Mathias CW, Dawes MA, Furr RM, Charles N, et al.
Author(s): Stott CG, White L, Wright S, Wilbraham D, Guy GW
Author(s): Fischer JS, Rudick RA, Cutter GR, Reingold SC
Author(s): Bohannon RW, Smith MB
Author(s): Endler NS, Rutherford A, Denisoff E
Author(s): Rog DJ, Nurmikko TJ, Friede T, Young CA
Author(s): Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P et al.
Author(s): Feinstein A
Author(s): Notcutt WG
Author(s): Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP et al.
Author(s): Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ et al.